Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease)
CRC Research Finding
The CRC Digest
The CRC Digest
Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease)